Efficacy and Safety of Diamyd® in Children and Adolescents With Type 1 Diabetes
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
This is a randomized, placebo-controlled phase II study to investigate if a prime and boost
of 20ug Diamyd® (rhGAD65 formulated in Alhydrogel®), administered subcutaneously four weeks
apart, is safe and can preserve beta cell function in children and adolescents with type 1
diabetes with a diabetes duration less than 18 months at intervention.